Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485039 · ClinicalTrials.gov registry record · Phase 4
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
A Phase 4 study, sponsored by SIGA Technologies.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT04485039 is a Phase 4 study that has completed, run by SIGA Technologies. The registered enrollment target is 44 participants.
The verdict
NCT04485039, a Phase 4 study, has completed, sponsored by SIGA Technologies.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
An open-label, drug-drug interaction study with TPOXX and phosphate binders.
Interventions
- DRUG Tecovirimat
- DRUG sevelamer carbonate oral tablet
- DRUG sucroferric oxyhydroxide chewable tablet
- DRUG calcium acetate oral tablet
- DRUG Lanthanum Carbonate Chewable Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2023-04-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04485039
The ClinicalTrials.gov registry entry for NCT04485039 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SIGA Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tecovirimat is the first listed.
NCT04485039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04485039 about?
NCT04485039 is a clinical study titled "Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders". An open-label, drug-drug interaction study with TPOXX and phosphate binders.
What is the current status of trial NCT04485039?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2022-06-08. Estimated completion is 2023-04-23.
What interventions are being tested in trial NCT04485039?
The interventions under investigation include: Tecovirimat (DRUG), sevelamer carbonate oral tablet (DRUG), sucroferric oxyhydroxide chewable tablet (DRUG), calcium acetate oral tablet (DRUG), Lanthanum Carbonate Chewable Tablet (DRUG).
Who is sponsoring clinical trial NCT04485039?
This trial is sponsored by SIGA Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.